The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

Aardvark Therapeutics (AARD) has drawn investor attention after voluntarily pausing its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome, following reversible cardiac observations at higher ...

Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance ...

Aardvark Therapeutics Inc. AARD shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome. The ...

Aardvark Therapeutics pauses Phase 3 HERO trial after cardiac safety observations, sending shares down nearly 61%.

Aardvark Therapeutics is down 54% since Friday after the biotech said it detected “reversible cardiac observations” in a healthy volunteer study of its drug to treat extreme hunger in patients with ...

Aardvark Therapeutics is voluntarily pausing a Phase 3 trial of a drug to treat hyperphagia in patients with Prader-Willi Syndrome. The biopharmaceutical company said it is pausing the trial after ...

Aardvark Therapeutics has seen its share price halve in value after the company paused a phase 3 study of its lead metabolic asset over heart-related data. The San Diego-based biotech has been ...

Feb 27 () - Aardvark Therapeutics on Friday said ‌it is voluntarily ‌pausing its late-stage trial testing its ​experimental treatment for a type of rare genetic disease. The company said the ...

Over the past several months, the social search service Aardvark has gained a lot of fans. But what’s somewhat peculiar is that most of those users interact with the site via email or IM, rather than ...